Skip to main content
. 2019 Jul 27;146(4):1075–1085. doi: 10.1002/ijc.32558

Figure 3.

Figure 3

Preclinical validation of ABT‐888 and NU7441 in HPV‐positive and HPV‐negative HNSCC xenografts. (a, e) Tumor volume curves of SCC154 and SQD9 xenografts treated with Vehicle (0.9% NaCl pH 4.0) or ABT‐888 (25 mg/kg) after RT. Day 1 indicates the start of treatment. Data are presented as mean ± SEM. *p‐value <0.05 were determined by ANOVA. (b, f) Ki67 immunostaining of SCC154 and SQD9 xenografts treated with Vehicle (0.9% NaCl pH 4.0) or ABT‐888 (25 mg/kg) after RT. (c, g) Tumor volume curves of SCC154 and SQD9 xenografts treated with Vehicle (40% PEG400 in 0.9% NaCl) or NU7441 (10 mg/kg) after RT. Data are presented as mean ± SEM. *p‐values <0.05 were determined by ANOVA. Day 1 indicates the first day of the treatment. (d, h) Ki67 immunostaining of SCC154 and SQD9 xenografts treated with Vehicle (40% PEG400 in 0.9% NaCl) or NU7441 (10 mg/kg) after RT. *p‐values <0.05 were calculated by two‐tailed t‐test. Scale bar, 100 μm. n = numbers of tumors.